Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-Enhanced CBCT in Radiotherapy
NCT04199754Phase 1Terminated
- Sponsor
- Columbia University
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iohexol in Abdominal cancer and Pelvic cancer, sponsored by Columbia University. Primary endpoints: Physician Survey of attitude about the utility of contrast-enhanced cone beam CT up to 18 Months and Blinded Match between contrast and non-contrast enhanced CBCT up to 18 Months. Started Oct 2020; status: terminated.
02
Drugs
iohexol
03
Conditions
Abdominal cancerPelvic cancer
Beyond the preview
Go deeper on NCT04199754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199754.